以上內容來自Benzinga Earnings專欄,原文如下:
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.23) by 73.91 percent. This is a 5.26 percent decrease over losses of $(0.38) per share from the same period last year.